Protein A Agarose (ab193254)
Key features and details
- Sample type: Ascites Fluid, Cell culture media, Cell culture supernatant, Serum
Overview
-
Product name
Protein A Agarose -
Sample type
Cell culture supernatant, Serum, Cell culture media, Ascites Fluid -
Product overview
High binding capacity (>20 mg IgG/mL). Minimal leaching of ligand. Suitable for column or batch purification of IgG, immunoprecipitation & ChIP (ab193254).
Contents:
Supplied as a 50% slurry in 20% Ethanol.
Features:
High binding capacity = Binding of IgG ≥ 20 mg human or rabbit IgG/mL Protein A Agarose.
Minimal leaching of the ligand
Flow Rate Tested* = 2.89 mL/min.
*Test condition: = Calculations based on the time required to pass 18 mL of water through 2 mL settled beads (column diameter 1.5 cm).
Usage = Reusable for up to 10 times without significant loss of binding capacity.
Store beads at 4°C.
The beads may be damaged above 40°C.
DO NOT FREEZE.
Wash beads 3 times with 3x bead volume of desired buffer before use.
Applications:
- Purification of monoclonal and polyclonal antibodies from culture media, serum, ascites fluid or hybridoma supernatants.
- Isolation of antibody/antigen complexes in immunoprecipitation experiments, since only the Fc region is involved in antibody binding and the Fab region is available for binding antigen. -
Notes
This product is manufactured by BioVision, an Abcam company and was previously called 6526 Protein A-Agarose. 6526-100 is the same size as the 100 ml size of ab193254.
Protein A Agarose beads are prepared by covalently coupling recombinant Protein A to 6% cross-linked Agarose beads, the most popular resin for protein affinity purification methods. Protein A is a genetically engineered protein containing five IgG-binding regions of native Protein A. The cell wall binding region, albumin binding region and other non-specific regions have been eliminated from the recombinant Protein A to ensure maximum specific IgG binding. The coupling technique is optimized to give a higher binding capacity for IgG and minimum leaching of recombinant Protein A compared to standard Protein A agarose beads. The IgG binding capacity of Protein A Agarose is ≥ 20 mg human or rabbit IgG per mL of wet beads. Protein A Agarose beads display high chemical and physical stability as well as high flow rate, hydrophilicity and high gel strength. This product can be used for IgG purification and immunoprecipitation.
-
Tested applications
Suitable for: IP, Purificationmore details
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 100 ml 1 ml 25 ml 5 ml 1 ml 5 ml 100 ml Protein A-Agarose 1 x 100ml 1 x 1ml 1 x 25ml 1 x 5ml 1 x 1ml 1 x 5ml 1 x 100ml -
Research areas
Associated products
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab193254 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| IP |
Use at an assay dependent concentration.
|
|
| Purification |
Use at an assay dependent concentration.
Purification of monoclonal and polyclonal antibodies from culture media, serum, ascites fluid or hybridoma supernatants. |
| Notes |
|---|
|
IP
Use at an assay dependent concentration. |
|
Purification
Use at an assay dependent concentration. Purification of monoclonal and polyclonal antibodies from culture media, serum, ascites fluid or hybridoma supernatants. |
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (10)
ab193254 has been referenced in 10 publications.
- Chivers SB et al. Raf kinase inhibitory protein reduces bradykinin receptor desensitization. J Neurochem 162:156-165 (2022). PubMed: 35526109
- Ji J et al. Lamin B2 contributes to the proliferation of bladder cancer cells via activating the expression of cell division cycle‑associated protein 3. Int J Mol Med 50:N/A (2022). PubMed: 35775376
- Han YH et al. Enterically derived high-density lipoprotein restrains liver injury through the portal vein. Science 373:N/A (2021). PubMed: 34437091
- Wu J et al. Two naturally derived small molecules disrupt the sineoculis homeobox homolog 1-eyes absent homolog 1 (SIX1-EYA1) interaction to inhibit colorectal cancer cell growth. Chin Med J (Engl) 134:2340-2352 (2021). PubMed: 34561318
- Yang C et al. Small molecule NSC1892 targets the CUL4A/4B-DDB1 interactions and causes impairment of CRL4DCAF4 E3 ligases to inhibit colorectal cancer cell growth. Int J Biol Sci 16:1059-1070 (2020). PubMed: 32140073
- Chen FX et al. Intramuscular accumulation of pentadecanoic acid activates AKT1 to phosphorylate NCOR1 and triggers FOXM1-mediated apoptosis in the pathogenesis of sarcopenia. Am J Transl Res 12:5064-5079 (2020). PubMed: 33042406
- Balcioglu O et al. CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress. Breast Cancer Res 22:125 (2020). PubMed: 33187540
- Cragle CE et al. Musashi interaction with poly(A)-binding protein is required for activation of target mRNA translation. J Biol Chem 294:10969-10986 (2019). PubMed: 31152063
- Santini SJ et al. SIRT1-Dependent Upregulation of Antiglycative Defense in HUVECs Is Essential for Resveratrol Protection against High Glucose Stress. Antioxidants (Basel) 8:N/A (2019). PubMed: 31480513
- Varnum MM et al. A split-luciferase complementation, real-time reporting assay enables monitoring of the disease-associated transmembrane protein TREM2 in live cells. J Biol Chem 292:10651-10663 (2017). PubMed: 28490631